Xeris Biopharma Holdings, Inc. $XERS Shares Newly Purchased by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC purchased a new position in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 133,378 shares of the company’s stock, valued at approximately $1,275,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in XERS. BlackRock Inc. purchased a new position in shares of Xeris Biopharma in the 2nd quarter worth about $115,042,000. Wellington Management Group LLP grew its holdings in shares of Xeris Biopharma by 8.9% during the 2nd quarter. Wellington Management Group LLP now owns 2,365,103 shares of the company’s stock worth $18,732,000 after purchasing an additional 193,749 shares during the period. Legal & General Group Plc acquired a new stake in Xeris Biopharma during the 2nd quarter worth approximately $15,941,000. Parkman Healthcare Partners LLC acquired a new stake in Xeris Biopharma during the 2nd quarter worth approximately $14,316,000. Finally, Algert Global LLC increased its position in Xeris Biopharma by 50.6% during the 2nd quarter. Algert Global LLC now owns 1,742,942 shares of the company’s stock worth $13,804,000 after purchasing an additional 585,984 shares in the last quarter. 42.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Kevin McCulloch sold 25,000 shares of the company’s stock in a transaction on Thursday, November 5th. The shares were sold at an average price of $12.49, for a total value of $312,250.00. Following the completion of the transaction, the insider directly owned 1,559,208 shares in the company, valued at approximately $19,474,507.92. This represents a 1.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 25,000 shares of the company’s stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total transaction of $255,750.00. Following the completion of the transaction, the insider owned 1,086,130 shares of the company’s stock, valued at $11,111,109.90. This trade represents a 2.25% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 168,332 shares of company stock valued at $1,678,971 over the last 90 days. 4.35% of the stock is owned by corporate insiders.

Xeris Biopharma Price Performance

XERS stock opened at $16.65 on Friday. The company has a debt-to-equity ratio of 3.89, a quick ratio of 1.02 and a current ratio of 2.15. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $16.88. The firm has a market cap of $3.04 billion, a P/E ratio of -332.93 and a beta of 0.61. The stock has a 50-day simple moving average of $10.24 and a 200-day simple moving average of $7.79.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.06 EPS for the quarter, topping the consensus estimate of $0.03 by $0.03. The firm had revenue of $107.23 million for the quarter, compared to analyst estimates of $101.68 million. Xeris Biopharma had a positive return on equity of 147.75% and a negative net margin of 1.76%. On average, equities analysts predict that Xeris Biopharma Holdings, Inc. will post 0.15 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on XERS shares. Leerink Partners lifted their price target on shares of Xeris Biopharma from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Thursday, September 10th. Oppenheimer reissued an “outperform” rating and issued a $21.00 price objective (up from $18.00) on shares of Xeris Biopharma in a research report on Friday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, November 4th. Barclays raised their target price on shares of Xeris Biopharma from $14.00 to $18.00 and gave the company an “overweight” rating in a research note on Wednesday. Finally, Wall Street Zen upgraded shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 7th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $17.00.

Xeris Biopharma Profile

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.